 |
25 Diseases |  |
0 Trials |
|
0 Trials |  |
46 News |  |
- ||| Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
Trial termination, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Dec 20, 2019
P2, N=14, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Terminated; Treatment Ineffective
- Zumagev (astuprotimut-R) / GSK
Phase classification: MAGRIT: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 25, 2019
P3, N=2278, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated; Treatment Ineffective Phase classification: P2/3 --> P3
- ||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zumagev (astuprotimut-R) / GSK
Enrollment change, Metastases: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (clinicaltrials.gov) - May 29, 2019
P2, N=44, Completed, Sponsor: M.D. Anderson Cancer Center
Phase classification: P2/3 --> P3 N=30 --> 44
- Zumagev (astuprotimut-R) / GSK
Phase classification: MAGRIT: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 30, 2019
P2/3, N=2278, Terminated, Sponsor: GlaxoSmithKline
N=30 --> 44 Phase classification: P3 --> P2/3
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zumagev (astuprotimut-R) / GSK
Trial completion, Trial completion date, Trial primary completion date, Metastases: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (clinicaltrials.gov) - Nov 27, 2018
P2, N=30, Completed, Sponsor: M.D. Anderson Cancer Center
Phase classification: P3 --> P2/3 Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> Nov 2018 | Trial primary completion date: Feb 2019 --> Nov 2018
- | Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
Trial completion date, Trial primary completion date, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Oct 3, 2018
P2, N=14, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> Nov 2018 | Trial primary completion date: Feb 2019 --> Nov 2018 Trial completion date: Mar 2020 --> Jul 2020 | Trial primary completion date: Mar 2019 --> Jul 2019
- Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
Trial primary completion date, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Jul 4, 2017
P2, N=14, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Mar 2020 --> Jul 2020 | Trial primary completion date: Mar 2019 --> Jul 2019 Trial primary completion date: Sep 2017 --> Sep 2018
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zumagev (astuprotimut-R) / GSK
Trial primary completion date, Metastases: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (clinicaltrials.gov) - Apr 13, 2017
P2, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Feb 2018 --> Feb 2019
- Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
Trial primary completion date, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Jan 24, 2017
P2, N=14, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Feb 2018 --> Feb 2019 Trial primary completion date: Mar 2017 --> Sep 2017
- Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
Trial primary completion date, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Aug 17, 2016
P2, N=14, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Sep 2016 --> Mar 2017
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zumagev (astuprotimut-R) / GSK
Trial primary completion date, Metastases: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (clinicaltrials.gov) - Apr 11, 2016
P2, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2016 --> Mar 2017 Trial primary completion date: Feb 2017 --> Feb 2018
- Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
Trial primary completion date, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Mar 11, 2016
P2, N=14, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: May 2016 --> Sep 2016
- Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
Trial primary completion date, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Nov 10, 2015
P2, N=14, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: May 2016 --> Sep 2016 Trial primary completion date: Jan 2019 --> May 2016
- Zumagev (astuprotimut-R) / GSK
Trial primary completion date: MAGRIT: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 22, 2015
P3, N=2278, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Jan 2019 --> May 2016 Trial primary completion date: Sep 2015 --> Dec 2013
- | Zumagev (astuprotimut-R) / GSK
Trial termination: A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor (clinicaltrials.gov) - Oct 22, 2015
P3, N=1351, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Sep 2015 --> Dec 2013 Active, not recruiting --> Terminated; The study was terminated early following assessment of the two co-primary endpoints showing the lack of efficacy of the study product.
- Zumagev (astuprotimut-R) / GSK
Trial primary completion date: MAGRIT: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 28, 2015
P3, N=2315, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated; The study was terminated early following assessment of the two co-primary endpoints showing the lack of efficacy of the study product. Trial primary completion date: Dec 2013 --> Sep 2015
- Zumagev (astuprotimut-R) / GSK
Trial primary completion date: A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor (clinicaltrials.gov) - Jul 20, 2015
P3, N=1351, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2013 --> Sep 2015 Trial primary completion date: Jun 2015 --> Sep 2015
- |||| Zumagev (astuprotimut-R) / GSK
Trial completion, IO biomarker, Metastases: PREDICT: A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma (clinicaltrials.gov) - Apr 23, 2015
P2, N=125, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Jun 2015 --> Sep 2015 Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zumagev (astuprotimut-R) / GSK
Trial primary completion date, Metastases: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (clinicaltrials.gov) - Apr 14, 2015
P2, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Feb 2017
- | Tice BCG (live attenuated bacillus Calmette-Guerin) / Merck (MSD), Texas A&M University, Zumagev (astuprotimut-R) / GSK
Trial completion, Trial primary completion date: BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients (clinicaltrials.gov) - Feb 5, 2015
P1, N=23, Completed, Sponsor: Patrice Jichlinski
Trial primary completion date: Feb 2016 --> Feb 2017 Enrolling by invitation --> Completed | Trial primary completion date: Apr 2014 --> Feb 2015
- | Zumagev (astuprotimut-R) / GSK
Trial completion, IO biomarker, Metastases: Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma (clinicaltrials.gov) - Jan 2, 2015
P2, N=24, Completed, Sponsor: GlaxoSmithKline
Enrolling by invitation --> Completed | Trial primary completion date: Apr 2014 --> Feb 2015 Active, not recruiting --> Completed
- | Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
Enrollment change, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Nov 19, 2014
P2, N=14, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed N=44 --> 14
- | Zumagev (astuprotimut-R) / GSK
Trial completion, Trial primary completion date, IO biomarker, Metastases: A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients (clinicaltrials.gov) - Nov 11, 2014
P2, N=48, Completed, Sponsor: GlaxoSmithKline
N=44 --> 14 Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Oct 2014
- |||| Zumagev (astuprotimut-R) / GSK
Trial primary completion date: A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor (clinicaltrials.gov) - Nov 5, 2014
P3, N=1351, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Oct 2014 Trial primary completion date: Apr 2013 --> Jun 2015
- | Zumagev (astuprotimut-R) / GSK
Trial termination: MAGRIT: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 29, 2014
P3, N=2278, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Apr 2013 --> Jun 2015 Active, not recruiting --> Terminated; The study was terminated following assessment of the lack of efficacy of the study product by the Independent Data monitoring Committee for the study.
- Zumagev (astuprotimut-R) / GSK
Trial primary completion date, IO biomarker, Metastases: A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients (clinicaltrials.gov) - Jul 14, 2014
P2, N=48, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated; The study was terminated following assessment of the lack of efficacy of the study product by the Independent Data monitoring Committee for the study. Trial primary completion date: Jun 2014 --> May 2016
- Zumagev (astuprotimut-R) / GSK
Trial termination, Metastases: MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma (clinicaltrials.gov) - Jun 24, 2014
P2, N=6, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Jun 2014 --> May 2016 Active, not recruiting --> Terminated; The study was terminated early due to difficulties in recruiting subjects, not following concerns for the safety or absence of clinical activity in patients.
- | Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
Enrollment closed, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Jun 19, 2014
P2, N=44, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Terminated; The study was terminated early due to difficulties in recruiting subjects, not following concerns for the safety or absence of clinical activity in patients. Recruiting --> Active, not recruiting
- Zumagev (astuprotimut-R) / GSK
Phase classification, IO biomarker, Metastases: A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients (clinicaltrials.gov) - Jun 12, 2014
P2, N=48, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Phase classification: P1 --> P2
- Zumagev (astuprotimut-R) / GSK
Trial primary completion date: Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 4, 2014
P1, N=71, Terminated, Sponsor: GlaxoSmithKline
Phase classification: P1 --> P2 Trial primary completion date: Nov 2014 --> Aug 2013
- Zumagev (astuprotimut-R) / GSK
Trial termination: Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 4, 2014
P1, N=71, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Nov 2014 --> Aug 2013 Active, not recruiting --> Terminated; Study early termination was due to slow recruitment and difficulties at achieving the required enrolment for the study.
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zumagev (astuprotimut-R) / GSK
Enrollment closed, Metastases: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (clinicaltrials.gov) - Jun 4, 2014
P2, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Study early termination was due to slow recruitment and difficulties at achieving the required enrolment for the study. Recruiting --> Active, not recruiting
- Zumagev (astuprotimut-R) / GSK
Trial completion date, IO biomarker, Metastases: A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients (clinicaltrials.gov) - May 14, 2014
P2, N=48, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Trial completion date: Jun 2014 --> May 2016
- || Zumagev (astuprotimut-R) / GSK
Enrollment closed: Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 11, 2013
P1, N=72, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial completion date: Jun 2014 --> May 2016 Recruiting --> Active, not recruiting
- Zumagev (astuprotimut-R) / GSK
Enrollment closed, Immune cell: Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI (clinicaltrials.gov) - Sep 18, 2013
P0, N=27, Active, not recruiting, Sponsor: Craig L Slingluff, Jr
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Zumagev (astuprotimut-R) / GSK
Enrollment change, IO biomarker, Metastases: Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma (clinicaltrials.gov) - Jul 10, 2013
P2, N=24, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting N=20 --> 24
- ||||| Zumagev (astuprotimut-R) / GSK
Enrollment closed: MAGRIT: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 9, 2013
P3, N=2278, Active, not recruiting, Sponsor: GlaxoSmithKline
N=20 --> 24 Recruiting --> Active, not recruiting
- ||| Zumagev (astuprotimut-R) / GSK
Enrollment closed, IO biomarker, Metastases: PREDICT: A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma (clinicaltrials.gov) - Aug 8, 2012
P2, N=125, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zumagev (astuprotimut-R) / GSK
Enrollment open, Metastases: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (clinicaltrials.gov) - Jun 5, 2012
P2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Completed --> Active, not recruiting Active, not recruiting --> Recruiting
- Tice BCG (live attenuated bacillus Calmette-Guerin) / Merck (MSD), Texas A&M University, Zumagev (astuprotimut-R) / GSK
Enrollment open: BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients (clinicaltrials.gov) - Feb 16, 2012
P1, N=24, Enrolling by invitation, Sponsor: Patrice Jichlinski
Active, not recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Zumagev (astuprotimut-R) / GSK
Trial initiation date, Metastases: High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (clinicaltrials.gov) - Feb 2, 2012
P2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Enrolling by invitation Initiation date: Feb 2011 --> Feb 2012
- Zumagev (astuprotimut-R) / GSK
Enrollment closed, IO biomarker, Metastases: A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients (clinicaltrials.gov) - Jan 12, 2012
P1, N=48, Active, not recruiting, Sponsor: GlaxoSmithKline
Initiation date: Feb 2011 --> Feb 2012 Recruiting --> Active, not recruiting
- Tice BCG (live attenuated bacillus Calmette-Guerin) / Merck (MSD), Texas A&M University, Zumagev (astuprotimut-R) / GSK
New P1 trial: BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients (clinicaltrials.gov) - Dec 5, 2011
P1, N=24, Enrolling by invitation, Sponsor: Patrice Jichlinski
- Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
Enrollment open, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Oct 11, 2011
P2, N=44, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Hiltonol (poly-ICLC) / Oncovir, Zumagev (astuprotimut-R) / GSK
New P2 trial, Metastases: Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - Sep 19, 2011
P2, N=44, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute